Menu Close

What the FDA’s accelerated approval of a new Alzheimer’s drug could mean for those with the disease

The U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an “accelerated approval pathway” that fast-tracks promising clinical treatments for diseases in which there are no other currently effective options.

Generated by Feedzy